About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline



5 Health L.J. 147 (1997)
Of Mice and Men: The Ethics of Patenting Animals

handle is hein.journals/hthlj5 and id is 151 raw text is: Of Mice and Men: The Ethics of Patenting Animals
Eileen Morn
I. Introduction
The patenting of the Harvard Onco-mouse, a mouse genetically altered for use
in cancer research, brought to the forefront the debate on the patenting of higher
life forms. Despite vocal opposition, the Harvard Onco-mouse (hereinafter the
Onco-mouse) was granted patent protection in the United States in 19881 and in
Europe in 1992.2 In Canada, however, the patent application was denied in 1995
by the Commissioner of Patents,3 and this decision is currently under appeal to the
Federal Court of Canada.4
The patenting of the transgenic mouse raises a host of ethical questions, but
the Commissioner's decision was a legal one based on the Canadian Patent Act.'
The patent was denied not because it is immoral to patent animals, but on the
grounds that the Onco-mouse was made primarily by nature, not by man. The
outcome of this appeal could affect an estimated 150 patent applications pending
'Eileen Morin is an articling student with Ontario Hydro. This paper was written for Professor B.M.
Dickens' course on medical jurisprudence at the University of Toronto, Faculty of Law. The author
would like to thank all those who assisted with this paper, including the editors, B.M. Dickens, C.
Ledgley, I. Ho, R. Osterwalder, B. Shea, and D. Vandergheynst.
'U.S. Patent No. 4,736,866. Filed 22 June, 1984; Date of Patent: 12 April, 1988.
'European Patent No. 0 169 672. The Examining Division of the European Patent Office (EPO)
published its decision as an annex to a form sent to the patentee on October 1991. The Onco-mouse
patent was granted 13 May, 1992. Opposition proceedings before the Opposition Division of the EPO
are still ongoing and the decision reached by the Opposition Division can still be appealed, according
to Rainer Osterwalder, Press Officer for the EPO. There was no indication as of August 1997 as to
when the Opposition Division would reach a decision.
'On 4 August, 1995, the Commissioner of Patents rejected Canadian patent application no. 484,723
of the President and Fellows of Harvard College, an invention entitled Transgenic Animals. The
Commissioner ruled that claims to a transgenic non-human mammal were not patentable subject matter
under Section 2 of the Patent Act, R.S.C. 1985, c. P4 butallowed claims for method and use claims.
The decision was not published. See J. Rudolph, C. Collard & C. Ledgley, Reporting of the
Biotechnology Legislation Committee (1996) 13 Can. Intell. Prop. Rev. 55 at 60.
'President and Fellows of Harvard College v. Commissioner of Patents, (F.C.T.D.) No. T-275-96. The
full title is: In the Matter of an Appeal from the Decision of the Commissioner of Patents dated August
4, 1995 in Canadian Patent Application Serial No. 484,723, of President and Fellows of Harvard
College for an Invention Entitled Transgenic Animals  President and Fellows of Harvard College
v. Commissioner of Patents, Notice of Appeal (2 February, 1996), No. T-275-96 (F.C.T.D.). The
appeal was heard on 17 November, 1997; the Federal Court (T.D.) reserved its decision, which had not
been issued as of 21 November, 1997.
'Patent Act, R.S.C. 1985, c.P-4.